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Background: COPD case finding is currently recommended at primary and tertiary care levels only.
Aim: To evaluate the feasibility of a community pharmacy program for COPD case finding in high-
risk customers by means of spirometry.
Methods: Pilot cross-sectional descriptive study in 13 urban community pharmacies in Barcelona,
Spain, fromApril toMay 2007. Customers>40 years oldwith respiratory symptoms and/or a history
of smoking were invited to participate in the study during pharmacists’ routine work shifts. High-
riskcustomerswere identifiedbymeansofa5-itemCOPDscreeningquestionnairebasedoncriteria
of the Global Initiative for Chronic Obstructive Lung Disease, and were invited to perform spirom-
etry accordingly. Those with an FEV1/FVC ratio less than 0.70 were referred to the hospital for
a repeat spirometry.
Results: Of the 161 pharmacy customers studied, 100 (62%) scored 3 or more items in the COPD
screening questionnaire, and after spirometry, 21 (24%) had an FEV1/FVC ratio< 0.7. When these
subjects with airflow limitation were offered referral to a hospital respiratory function laboratory
for further assessments, 11 (52%) attended the appointment. Over 70% of spirometries were rated
as being of acceptable quality. No significant differences were observed in lung function parame-
ters between the pharmacy and hospital measurements.eumologia, Hospital del Mar, Institut Municipal d’Investigacio´ Me`dica (IMIM), Passeig Marı´tim 25-29,
2483138; fax: þ34 93 2483425.
com (D. Castillo).
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840 D. Castillo et al.Conclusions: COPD case finding by spirometry in high-risk customers of urban community pharma-
cies is feasible. Similarly to primary care practitioners, pharmacists have access to high-risk,
middle-aged subjects who have never been tested for COPD. Pharmacists can help with early
detection of COPD if they are correctly trained.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Early diagnosis of COPD is important because smokers with
demonstrated airway obstruction are more likely to quit
smoking.1 Recently, the U.S. Preventive Services Task Force
(USPSTF) recommended against screening the general
population for chronic obstructive pulmonary disease
(COPD) using spirometry (grade D recommendation).2
However, the same document recognised that individuals
presenting respiratory symptoms (chronic cough, increased
sputum production, wheezing, or dyspnea) should be
tested. This position is consistent with the recommenda-
tions of other relevant groups: the American Thoracic
Society (ATS) and the European Respiratory Society (ERS)
advise performing spirometry on all persons with smoking
exposure, a family history of chronic respiratory illness, or
respiratory symptoms,3 and the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) recommends that clini-
cians consider a diagnosis of COPD ‘in any patient who has
dyspnea, chronic cough or sputum production, and/or
a history of exposure to risk factors for the disease’ and
that the ‘diagnosis should be confirmed by spirometry’.4
At present, detection of COPD is limited to case finding
at the primary or tertiary care levels, a strategy that has
proven largely inadequate. One large population-based
survey showed that a high percentage (63%) of subjects
with airflow limitation had never received a diagnosis of
obstructive lung disease.5 In Spain, underdiagnosis has been
estimated to be around 80%.6
Pharmaceutical care, which has been useful in the
management of ambulatory patients with chronic diseases
such as asthma,7 might offer a new approach to COPD case
finding. Community pharmacists trained to perform
spirometry have been successful in improving access to lung
function measurement in rural communities,8 and we
hypothesized that they might also be able to help in an
urban general population. For such an approach to work,
the pharmacist would need to be able to select high-risk
individuals in whom spirometry should be performed. The
aim of this pilot study was to assess the feasibility of
a program of case finding of COPD by spirometry in
community pharmacies.
Methods
Pharmacist selection and training
To recruit pharmacist participants, we contacted commu-
nity pharmacies in a smoking prevention group formed
through the professional association for this sector (Official
College of Pharmacists, COFB) in Barcelona, Spain. The
study had been approved by the ethics committee ofHospital Clinic i Provincial, Barcelona. Thirteen of the 19
members of the smoking prevention group accepted,
agreeing that a staff pharmacist would attend a four-day
spirometry training course in February and March 2007.
Training was based on the guidelines of the National Insti-
tute for Occupational Safety and Health (NIOSH),9 the ERS/
ATS,10 and the Spanish Society of Pulmonology and Thoracic
Surgery (SEPAR).11 The volunteer pharmacists recruited
subjects from among customers arriving during their regular
work shifts of about 8 h per day and they conducted
interviews and tests between attending customers. The
daily routine of the pharmacy was not modified so that our
results would not overestimate the number of new cases of
COPD that can be found by this route in real conditions.
Spirometer and assessment procedures
The portable spirometer (Easy-One Spirometer, ndd Medical
Technologies, Zu¨rich, Switzerland) was chosen because it is
easy to handle and has been used in other population
screening studies.12 Calibration was checked at the begin-
ning of the study and did not have to be re-checked daily.
The device has built-in software that ranks spirometry
quality (grades AeF) in accordance with standard European
classifications.10 An A or B rating indicated acceptable
quality, because both levels supposed three good
manoeuvres with at least two readings of forced vital
capacity (FVC) and forced expiratory volume in 1 s (FEV1)
differing by <150e200 ml. In addition, an expert in lung
function (F.B.) reviewed and rated all spirometry curves
according to the same criteria.
Lung function measurements included FEV1, FVC and the
FEV1/FVC ratio. FEV1 and FVC were expressed in liters and
as the percentage of reference values for the Spanish
population.13 According to the Spanish COPD guidelines,14
and as recently proposed elsewhere for mass screening
programs,15 we used pre-bronchodilator lung function to
classify airflow limitation, defined by an FEV1/FVC
ratio< 0.70.
Subject selection and evaluation
During April and May 2007, customers who entered the
participating community pharmacies and who seemed to be
in the targeted age range (>40 years) were approached
with opening questions about respiratory symptoms or
smoking. If a candidate expressed interest in the topic, the
pharmacist explained the objectives of the research and
the voluntary nature of participation. Participants signed
a consent form if interested, and the pharmacist then asked
about previous diagnoses of lung disease or use of inhaled
medication and sociodemographic data as stipulated by
COPD case finding by spirometry 841a written questionnaire. Individuals aged< 40 years or who
had a history of lung disease or use of inhalers were
excluded at this time. To assess the risk of COPD, we used
the GOLD screening questionnaire, as recommended in the
2006 guidelines.4 This questionnaire consisted of questions
on five items referring to more breathlessness than people
of the same age, chronic cough, chronic sputum, age> 40
years, and smoking. Subjects with 3 affirmative answers
were offered spirometry. Those in whom the FEV1/FVC
ratio was <0.70 were referred to a lung function unit in
a university hospital (Hospital de la Santa Creu i Sant Pau or
Hospital Clinic I Provincial, both in Barcelona). Within
24e48 h spirometry was repeated by an expert nurse using
the same brand of spirometer. Refusal to continue partici-
pating in the study was recorded with the specified reason.
Smokers were also encouraged to quit smoking through
a cessation program, as giving this advice was part of the
normal routine for these volunteer community pharmacists.
Statistical methods
Descriptive data of participants and subgroups are pre-
sented as mean and standard deviation unless otherwise
stated. We compared participants with a low and high COPD
risk, and spirometry data in the normal and abnormal
groups, using t-tests for normally distributed parametric
data and the KolmogoroveSmirnov test for non-parametric
data (quality spirometry, gender, tobacco exposure and
GOLD screening score). Using the Wilcoxon rank sum test
we compared each subject’s expiratory flow rates
measured at the pharmacy and the hospital. A BlandeAlt-
man graph was also created to show individual differences
between pharmacy and hospital FEV1 values. Statistical
significance was set at P 0.05 for comparisons between
groups. All analyses were performed using the Statistical
Package for Social Sciences (SPSS) for Windows, version
15.0 (SPPS Inc., Chicago, Illinois, USA).
Results
A total of 254 customers approached by the pharmacists
expressed interest in the study; 188 (74%) agreed to
participate by signing the consent form after the nature of
the study was explained. Reasons given by the 66 subjects
who declined to participate included no time to wait
(nZ 28, 42%), no interest (nZ 12, 18%), already diagnosed
with a respiratory condition (nZ 14, 21%) and others
(nZ 12, 18%). Twenty-seven of these 188 initial partici-
pants were excluded by the pharmacists when criteria were
reviewed; reasons for exclusion at this time were age< 40
years or previous lung disease (Fig. 1).
The 161 remaining volunteers agreed to fill in the GOLD
screening questionnaire for COPD. The average age of these
participants was 55 11 years, 94 (58%) were women, and
124 (77%) were smokers or ex-smokers. The mean GOLD
screening score was 3.0 1.2. Sixty-one of the 161
respondents (38%) had a score< 3 and 100 (62%) a score of
3, indicating they were at high risk for COPD (Table 1).
The age and proportion of women in the two groups were
similar. More high-risk customers were smokers or
ex-smokers, and they also had a higher mean GOLDscreening score than those at low risk. Those in the high-
risk group were offered spirometry; only three refused and
one was excluded because she was ill with a respiratory
infection at that time. Customers who attended spirometry
had at least one symptom. Chronic cough was the most
common (66%) but each symptom was present in about half
the subjects (chronic sputum 54%, breathlessness 63%).
Low-risk subjects were more frequently asymptomatic
(chronic cough 6%, chronic sputum 5%, breathlessness 3%).
Thus, 96 high-risk subjects performed spirometry in the
pharmacy. Sixty-five (68%) had an FEV1/FVC% ratio 0.70
and 21 (22%) had an FEV1/FVC% ratio< 0.70, indicating
airflow limitation. The distribution of airflow limitation by
age is shown in Fig. 2. Ten were unable to perform the
manoeuvres correctly. Personal characteristics and
spirometry results for those who performed a correct
spirometry are shown in Table 2. According to our pre-
bronchodilator data, airflow limitation was mild in 13 (62%)
of the subjects in whom it was detected, moderate in 7
(33%) and severe in 1 (5%).
Out of the 86 patients who underwent spirometry,
airflow limitation (FEV1/FVC ratio< 0.70) was detected in
21 (24%), and they were invited for referral to a hospital
pulmonary function laboratory for further assessment. Only
11 (52%) subjects both accepted referral and actually went
to the laboratory. In all cases, the airway obstruction was
confirmed. Moreover, the lung function values recorded in
the community pharmacy and in the hospital pulmonary
function laboratory were similar in both settings (FEV1,
PZ 0.5; FVC, PZ 0.89; and FEV1/FVC ratio, PZ 0.14)
(Fig. 3). Of note, among those referred to the hospital, two
presented a pre-bronchodilator FEV1< 60%.
Finally, spirometric curves in the pharmacy were of
acceptable quality overall, with 70% rated as A or B quality
by the spirometer software and 73% were considered of
acceptable quality by the lung function expert. The quality
rating tended to be even better in subjects with airflow
limitation, 76% of whom were considered to have A or B
quality curves, but the difference was not significant
(PZ 0.71).Discussion
Individuals at high risk for COPD can be detected by
spirometry screening undertaken by adequately trained
pharmacists in urban community pharmacies. Our data
show that pharmacists were able to identify customers with
respiratory symptoms and/or smokers in a population in
which the majority were middle-aged subjects who had
never been tested for COPD. Furthermore, the pharmacists
were able to supervise high quality spirometry manoeuvres
in 70% of subjects, finding one case of airflow limitation for
every five individuals tested, a rate that was similar to that
reported for the UK primary care setting.16
Spirometry in the primary care setting has been shown
to be useful in screening for COPD and it continues to be
promoted as the means for diminishing the population
underdiagnosis of this disease.17 Additionally, the
usefulness of reporting individual lung age to smokers has
been elegantly confirmed recently.19 However, lack of
technical or human resources in primary care is a limiting
FEV1/FVC < 0.70Incorrect manoeuvre FEV1/FVC ≥ 0.70
61 subjects
GOLD questionnaire
Pharmacy customers, mainly former or current 
smokers or those with respiratory symptoms 
254 subjects invited to participate
161 included66 refuse:
No time to wait, 28
No interest, 12
Previously diagnosed, 14
Other, 12
27 excluded:
Age <40, 15
History of lung disease, 12
<3 items ≥3 items
100 subjects
Spirometry proposed
Excluded:
3 refuse
1 ill
10 subjects 21 subjects 65 subjects
Hospital referral
11 Accept 10 Refuse
Figure 1 Flow chart showing subject processing from pharmacy to hospital referral.
842 D. Castillo et al.factor,18 compounded by primary care physicians’ low
rate of request for spirometry.20 Therefore, under-
diagnosis in the primary care setting continues to be
inordinately common.21 In this pilot study, our findingTable 1 Characteristics of the participating pharmacy custome
All customers (nZ 161)
Age, mean SD 55 11
Women, n (%) 94 (58)
Smoking history, n (%) 124 (77)
GOLD score, mean SD 3.0 1.2
a Significant differences were found between low-risk and high-risk g
GOLD score (PZ 0.01). GOLDZGlobal Initiative for Chronic Obstructthat the community pharmacy can provide a complemen-
tary setting for COPD case finding in the general pop-
ulation offers hope of improving the health care system’s
screening potential.rs.
Low risk (nZ 61) High risk (nZ 100)
56 11 55 11
38 (62) 56 (56)
36 (59) 88 (88)a
1.7 0.4 3.8 0.8a
roups for smoking history (smokers or ex-smokers) (PZ 0.01) and
ive Lung Disease.
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Figure 2 Distribution of percent predicted FEV1 by age for all
participants (subjects with airflow limitation are represented
by filled circles).
COPD case finding by spirometry 843Widespread use of spirometry in screening for COPD has
been questioned.2 The current recommendations are to
study subjects at high risk.2e4 All subjects offered spirom-
etry in our study were in fact symptomatic as detected by
the questionnaire, suggesting that inappropriate resource
consumption can be kept under control by applying a GOLD-
criteria-based screening questionnaire. Our use of the
GOLD screening questionnaire to assess the risk of COPD
followed recommendations in the 2006 guidelines,4
although recently validated questionnaires with the same
goal are available elsewhere.22
Our study also shows that pharmacists can obtain valid
spirometries if they are well-trained and highly motivated.
Seventy percent of the spirometry curves were judged to be
of A- or B-level quality after review by an expert in lung
function testing; that success rate was higher than the
reported 63% in a previous pharmacy study.8 Only 10% of
the subjects who were invited to perform spirometry in the
community were unable to produce correct manoeuvres
under the pharmacists’ supervision, a situation quite similar
to that reported for the primary care level.23 The quality of
spirometry was also reflected in the lack of differences in
results in pharmacy and hospital measurements for the
same subjects.Table 2 Characteristics and respiratory function data for subjec
FEV1/FVC ratio as having normal (ratio 0.70) or reduced airflow
All spirometries
(nZ 86)
Women, n (%) 49 (57)
Age (y) 55 11
Smoking history, n (%) 74 (86)
GOLD score 3.8 0.8
BMI 27.1 5.1
FEV1 (l) 2.5 0.7
FEV1 (% ref. val.) 86 0.2
FVC (l) 3.4 0.9
FVC (% ref. val.) 89 (0.2)
FEV1/FVC ratio 0.76 (0.1)
Data are expressed as mean SD unless otherwise noted.
a Significant differences in BMI (PZ 0.03), FEV1 (PZ 0.01), FEV1% (P
normal and abnormal spirometry groups.
FEV1Z forced expiratory volume in 1 s; FVCZ forced vital capacity; aAn interesting finding was the predominance of women
among the pharmacy customers. Given that the prevalence
of COPD in Spain has been found to be 14.3% in men and
3.9% in women in a population-based study,6 we expected
males to predominate among the tested subjects.
However, women accounted for 58% of the subjects and
57% of the positive spirometries. The pharmacy seems to
be a particularly good setting, therefore, to find cases in
women, among whom the prevalence of COPD seems to be
rising.24
A limitation of this study was the absence of a broncho-
dilator test. Although most guidelines recommend the use
of post-bronchodilator spirometry to diagnose and stage
COPD, other authors call for simplicity, especially for large-
scale screening.15,25,26 We ruled out the use of post-bron-
chodilator tests in pharmacies because of evident concerns
about practicality, safety, and efficiency. Should this
approach be implemented, we continue to consider that
bronchodilator tests should be performed in the hospital
laboratory after referral. Another limitation and the main
logistical problem of this study is related to referral of
subjects with possible COPD from the community pharmacy
to the hospital. In our study, nearly half of those with
spirometry results indicating airflow limitation declined
a hospital appointment. No time or lack of interest were
the reasons most often stated. We suspect that declining
referral may reflect either a lack of interest in quitting
smoking or milder disease. The general population has little
knowledge about COPD,27 in comparison with other condi-
tions such as cardiovascular disease, and they, therefore,
do not consider respiratory disease to be a serious personal
threat.
To conclude, in this pilot study, we have shown that
COPD case finding by spirometry in urban community
pharmacies is feasible. Pharmacists have access to high-
risk, middle-aged subjects who have never been tested for
COPD, and if the pharmacists are correctly trained, they
can detect airflow limitation by spirometry with results that
are similar to those previously reported at primary care
level. Pharmacists are health service professionals who are
not presently involved in screening for COPD but whosets who performed spirometry correctly and were classified by
.
Normal spirometry
(nZ 65)
Airflow limitation
(nZ 21)
37 (57) 12 (57)
54 10 57 12
56 (86) 18 (86)
3.8 0.8 3.7 0.8
27.8 4.7 25 5.7a
2.7 0.6 2.1 0.7a
91 0.1 72 0.1a
3.4 0.9 3.24 1.0
90 (0.2) 85 (0.1)
0.79 (0.1) 0.64 (0.1)a
Z 0.01) and FEV1/FVC ratio (PZ 0.01) were found between the
nd GOLDZGlobal Initiative for Chronic Obstructive Lung Disease.
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Figure 3 BlandeAltman graph for comparison of the phar-
macy- versus hospital-obtained percent predicted FEV1.
844 D. Castillo et al.participation may represent a useful complementary
strategy for early case finding.
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